Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) insider Gwenn Hansen sold 1,412 shares of the business's stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $11.78, for a total value of $16,633.36. Following the sale, the insider now owns 23,009 shares in the company, valued at $271,046.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Nurix Therapeutics Trading Up 0.6 %
Shares of NRIX traded up $0.07 during trading hours on Wednesday, hitting $12.36. 264,824 shares of the stock traded hands, compared to its average volume of 289,377. Nurix Therapeutics, Inc. has a 1-year low of $7.52 and a 1-year high of $20.20. The firm has a market capitalization of $582.75 million, a PE ratio of -3.32 and a beta of 1.63. The business has a fifty day moving average of $11.65 and a 200-day moving average of $13.46.
Get
Nurix Therapeutics alerts:
Analysts Set New Price Targets
A number of analysts have weighed in on the company. Morgan Stanley assumed coverage on Nurix Therapeutics in a research report on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 price target on the stock. SVB Leerink lowered their price target on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a research report on Tuesday, December 13th. Finally, HC Wainwright lowered their price target on Nurix Therapeutics to $53.00 in a research report on Thursday, October 13th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $32.90.
Hedge Funds Weigh In On Nurix Therapeutics
Large investors have recently made changes to their positions in the company. Los Angeles Capital Management LLC lifted its stake in shares of Nurix Therapeutics by 410.0% during the third quarter. Los Angeles Capital Management LLC now owns 67,655 shares of the company's stock valued at $882,000 after acquiring an additional 54,390 shares during the period. Amalgamated Bank acquired a new position in shares of Nurix Therapeutics during the first quarter valued at $70,000. Denali Advisors LLC acquired a new position in shares of Nurix Therapeutics during the third quarter valued at $47,000. ARK Investment Management LLC increased its holdings in Nurix Therapeutics by 65.2% in the third quarter. ARK Investment Management LLC now owns 1,286,522 shares of the company's stock valued at $16,763,000 after purchasing an additional 507,797 shares during the last quarter. Finally, DAFNA Capital Management LLC increased its holdings in Nurix Therapeutics by 4.3% in the second quarter. DAFNA Capital Management LLC now owns 566,695 shares of the company's stock valued at $7,180,000 after purchasing an additional 23,351 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company's stock.
Nurix Therapeutics Company Profile
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
